ライフサイエンスコーパス: the risk of

1 The risk of any AD and several individual ADs was consistentl

2 The risk of developing AF was 21.99 times higher (95% confide

3 The risk of incident ASCVD may be estimated in patients with

4 The risk of re-presentation with vivax malaria within 1 year

5 tivariate analysis showed that echinocandin therapy altered the risk of clinical failure.

6 Although the risk of HF remained elevated among those with cAVB in the

7 Based on multivariable analysis, the risk of primary nonadherence was 16 percentage points low

8 the highest and lowest intakes of nuts or peanut butter and the risk of gastric cardia adenocarcinoma, esophageal adenoca

9 ate local human immunodeficiency virus (HIV) RNA levels and the risk of sexual HIV transmission.

10 HMGCR scores, changes in lipid and lipoprotein levels, and the risk of cardiovascular events involving 102837 participan

11 events by 25% (P=0.037) during the initial trial phase and the risk of coronary heart disease death, cardiovascular deat

12 of bias were assessed using the Newcastle-Ottawa Scale and the Risk of Bias in Non-randomized Studies of Interventions t

13 nes during WL and a period of weight stabilization (WS) and the risk of weight regain.In this randomized controlled trial

14 sociation with avidity index and DNAemia may help to assess the risk of HCMV fetal transmission.

15 Our objective was to assess the risk of posttransplant cancer in this patient group.

16 Clinicians should consider the risk of perforation and counsel patients/families accordi

17 Among patients with cirrhosis, statin use decreased the risk of decompensation, mortality, and HCC in a dose-depe

18 We used a matched case-cohort design to estimate the risk of deaths by suicide and attempted suicide in indivi

19 In a large prospective cohort study, we evaluated the risk of breast cancer in relation to indoor heating and c

20 the claim that supplementation leads to a large increase in the risk of advanced AMD in some genotype subgroups.

21 density of health facilities resulted in a 25% reduction in the risk of death (HRR = 0.73, 95% CI:0.58 to 0.91) and accou

22 A number of factors can increase the risk of FGR, one of which is poor maternal diet.

23 Longstanding diabetes might increase the risk of acute rejections.

24 le micronutrient supplements did not significantly increase the risk of stillbirth or neonatal, 6-month, or infant mortal

25 ther advanced maternal age at birth independently increases the risk of low birth weight (<2,500 g) and preterm birth (<3

26 To investigate whether HIV infection increases the risk of future HFrEF and HFpEF and to assess if this risk

27 -positive patients without PBC is increased irrespective of the risk of PBC development.

28 model is a quick accurate tool to aid clinical judgment of the risk of seizures in critically ill patients.

29 ring beyond that recommended would lead to more lowering of the risk of left ventricular hypertrophy (LVH) in patients wi

30 System [WHOLIS], and Scopus) and sought unpublished data on the risk of NDI after invasive GBS disease in infants <90 day

31 The efficacy of NHE inhibitors on the risk of cardiovascular events may be enhanced when heart

32 Multivariable Cox proportional hazards regression models on the risk of a disease milestone and death were used.

33 ed that the effect of malaria infection during pregnancy on the risk of low birthweight (LBW; <2,500 g) may depend upon m

34 ompared to presurgery months 13-24 as the reference period, the risk of ED visit or hospitalization in the 0- to 12-month

35 Two questions that presented the risk of AK as not progressing to cancer had the lowest pr

36 t provides this advantage at the cost of modestly promoting the risk of autoimmunity.

37 ional HRCT diagnostic criteria based on the results to rank the risk of PTB.

38 These results suggest that novel oral anticoagulants reduce the risk of intraocular bleeding by approximately one-fifth c

39 s milk and avoidance of bovine-origin products might reduce the risk of necrotising enterocolitis, but the absolute reduc

40 ase and impaired glucose tolerance, acarbose did not reduce the risk of major adverse cardiovascular events, but did redu

41 cies in optisol-GS and should be further explored to reduce the risk of infection.

42 ng individuals with LDL-C >/=190 mg/dL, pravastatin reduced the risk of coronary heart disease by 27% (P=0.033) and major

43 tive to placebo, evolocumab treatment significantly reduced the risk of the primary end point (1344 patients [9.8%] vs. 1

44 This variant reduces the risk of severe malaria by 40% and has recently increased

45 Assessing liver health may be important for reducing the risk of future CHF events, particularly among HIV and hep

46 linical benefits of nepafenac 0.3% over vehicle in reducing the risk of postoperative ME, with the integrated analysis sh

47 hy (LVH) in patients with hypertension and whether reducing the risk of LVH explains the reported cardiovascular disease

48 Conclusion SRU consensus guidelines effectively stratified the risk of neoplasia and malignancy.

49 e the benefits of the enhanced host catabolic activity with the risk of being eliminated by the cell's cytosolic immune d

50 nd peanut butter consumption were inversely associated with the risk of gastric noncardia adenocarcinoma.

51 o evaluate the associations of ASB and SSB consumption with the risk of developing DM and the potential benefit of replac